Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-pentixather is a radiopharmaceutical diagnostic agent used in positron emission tomography (PET) imaging. It is a gallium-68 labeled peptide that targets the chemokine receptor CXCR4, which is overexpressed in various hematological malignancies and some solid tumors. The compound enables non-invasive visualization of CXCR4 expression, aiding in the assessment of tumor burden and disease staging, particularly in multiple myeloma and other cancers. 68Ga-pentixather serves as the diagnostic counterpart to therapeutic agents such as 177Lu/90Y-pentixather for theranostic applications. Its mechanism involves binding to CXCR4 on malignant cells, allowing PET imaging to detect areas of high receptor expression[1][7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 68ga-pentixather.